Total raised
$45.4M
Last: PIPE 2021-11
Stage
Mature
Founded
2008
Headcount
29
HQ
Ness Ziona
Sector
Health Tech & Life Sciences
About
NewCelX is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company’s integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes.
Funding history · 4 rounds · $45.4M total
2021-11
PIPE
$3.2M
2021-10
PIPE
$5.0M
2021-04
PIPE
$6.8M
2018-10
PIPE
$5.2M
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What was NewCelX's former name?
- NewCelX was formerly known as Kadimastem.
- When did NewCelX become a public company on NASDAQ?
- NewCelX became public on NASDAQ in October 2025.
- What was the total amount raised by NewCelX through funding rounds?
- NewCelX has raised a total of $45,352,000 through funding rounds. For a full financing history, please refer to startupim.
- Which investors participated in NewCelX's PIPE round in April 2021?
- In April 2021, Alpha Capital and Clover Wolf Capital were lead investors in NewCelX's PIPE round.
- When did NewCelX receive a grant from the IIA for $882,000?
- NewCelX received a grant of $882,000 from the IIA in July 2025.
- What was a significant operational development for NewCelX in March 2026?
- In March 2026, NewCelX announced a strategic collaboration with Eledon Pharmaceuticals to advance its NCEL-101 program for Type 1 Diabetes.
- What was the outcome of the merger between NLS Pharmaceutics Ltd. and Kadimastem Ltd. in October 2025?
- In October 2025, NLS Pharmaceutics Ltd. and Kadimastem Ltd. announced the completion of their merger, leading to NewCelX's NASDAQ listing.
- What patent did Kadimastem receive in India in February 2024?
- In February 2024, Kadimastem received a patent in India for its cell selection and enrichment technology used in its IsletRx treatment for diabetes.
- What was the result of Kadimastem and iTolerance's Pre-IND meeting with the FDA in February 2025?
- In February 2025, Kadimastem and iTolerance successfully completed a Pre-IND meeting with the FDA for their Type 1 Diabetes treatment.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
pharma-companiesstem-cellsdiabetesdegenerative-diseasesbioprocessneurologycell-therapyregenerative-medicinebiological-therapyamyotrophic-lateral-sclerosis-als